2014
DOI: 10.1371/journal.pone.0098315 View full text |Buy / Rent full text
|
|

Abstract: The humanized anti-CD22 antibody, epratuzumab, has demonstrated therapeutic activity in clinical trials of lymphoma, leukemia and autoimmune diseases, treating currently over 1500 cases of non-Hodgkin lymphoma, acute lymphoblastic leukemias, Waldenström’s macroglobulinemia, Sjögren’s syndrome, and systemic lupus erythematosus. Because epratuzumab reduces on average only 35% of circulating B cells in patients, and has minimal antibody-dependent cellular cytotoxicity and negligible complement-dependent cytotoxic… Show more

Help me understand this report

Search citation statements

Order By: Relevance
0
0
0
0
0
0
17
0

Publication Types

Select...

Relationship

0
0

Authors

Journals